Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study - PubMed (original) (raw)
. 2001 Apr 1;153(7):619-27.
doi: 10.1093/aje/153.7.619.
S E Holte, D Metzger, B A Koblin, M Gross, C Celum, M Marmor, G Woody, K H Mayer, C Stevens, F N Judson, D McKirnan, A Sheon, S Self, S P Buchbinder
Affiliations
- PMID: 11282787
- DOI: 10.1093/aje/153.7.619
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study
G R Seage 3rd et al. Am J Epidemiol. 2001.
Abstract
Questions exist about whether testing of preventive human immunodeficiency virus (HIV)-1 vaccines, which will require rapid recruitment and retention of cohorts with high HIV-1 seroincidence, is feasible in the United States. A prospective cohort study was conducted in 1995-1997 among 4,892 persons at high risk for HIV infection in nine US cities. At 18 months, with an 88% retention rate, 90 incident HIV-1 infections were observed (1.31/100 person-years (PY), 95% confidence interval (CI): 1.06, 1.61). HIV-1 seroincidence rates varied significantly by baseline eligibility criteria--1.55/100 PY among men who had sex with men, 0.38/100 PY among male intravenous drug users, 1.24/100 PY among female intravenous drug users, and 1.13/100 PY among women at heterosexual risk-and by enrollment site, from 0.48/100 PY to 2.18/100 PY. HIV-1 incidence was highest among those men who had sex with men who reported unprotected anal intercourse (2.01/100 PY, 95% CI: 1.54, 2.63), participants who were definitely willing to enroll in an HIV vaccine trial (1.96/100 PY, 95% CI: 1.41, 2.73), and women who used crack cocaine (1.62/100 PY, 95% CI: 0.92, 2.85). Therefore, cohorts with HIV-1 seroincidence rates appropriate for HIV-1 vaccine trials can be recruited, enrolled, and retained.
Similar articles
- Will preventive HIV vaccine efficacy trials be possible with female injection drug users?
Meyers K, Metzger DS, McLellan AT, Navaline H, Sheon AR, Woody GE. Meyers K, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):577-85. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 8548338 - Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate.
Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Buchbinder SP, et al. J Infect Dis. 1996 Nov;174(5):954-61. doi: 10.1093/infdis/174.5.954. J Infect Dis. 1996. PMID: 8896495 Clinical Trial. - HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary.
Beyrer C. Beyrer C. Clin Infect Dis. 2007 Apr 1;44(7):981-7. doi: 10.1086/512371. Epub 2007 Feb 26. Clin Infect Dis. 2007. PMID: 17342654 Review. - HIV vaccine evaluation center in Rio de Janeiro, Brazil.
Schechter M. Schechter M. Vaccine. 2002 May 6;20(15):1909-11. doi: 10.1016/s0264-410x(02)00065-8. Vaccine. 2002. PMID: 11983243 Review.
Cited by
- Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.
Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim AG, McNaughton AL, Trickey A, Ward Z, Abramovitz D, Alary M, Astemborski J, Bruneau J, Clipman SJ, Coffin CS, Croxford S, DeBeck K, Emanuel E, Hayashi K, Hermez JG, Low-Beer D, Luhmann N, Macphail G, Maher L, Palmateer NE, Patel EU, Sacks-Davis R, Van Den Boom W, van Santen DK, Walker JG, Hickman M, Vickerman P; HIV and HCV Incidence Review Collaborative Group. Artenie A, et al. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):533-552. doi: 10.1016/S2468-1253(23)00018-3. Epub 2023 Mar 27. Lancet Gastroenterol Hepatol. 2023. PMID: 36996853 Free PMC article. - Feasibility of conducting HIV prevention trials among key populations in Nairobi, Kenya.
Mutisya EM, Muturi-Kioi V, Abaasa A, Nyasani D, Kabuti RW, Lunani L, Kotikot T, Mundia M, Mutua G, Ombati G, Nduta H, Price MA, Kimani J, Anzala AO. Mutisya EM, et al. BMC Public Health. 2022 Dec 20;22(1):2385. doi: 10.1186/s12889-022-14875-2. BMC Public Health. 2022. PMID: 36536335 Free PMC article. - Rates of New Human Immunodeficiency Virus (HIV) Diagnoses After Reported Sexually Transmitted Infection in Women in Louisiana, 2000-2015: Implications for HIV Prevention.
Newman DR, Rahman MM, Brantley A, Peterman TA. Newman DR, et al. Clin Infect Dis. 2020 Mar 3;70(6):1115-1120. doi: 10.1093/cid/ciz303. Clin Infect Dis. 2020. PMID: 30976788 Free PMC article. - Does per-act HIV-1 transmission risk through anal sex vary by gender? An updated systematic review and meta-analysis.
Baggaley RF, Owen BN, Silhol R, Elmes J, Anton P, McGowan I, van der Straten A, Shacklett B, Dang Q, Swann EM, Bolton DL, Boily MC. Baggaley RF, et al. Am J Reprod Immunol. 2018 Nov;80(5):e13039. doi: 10.1111/aji.13039. Epub 2018 Sep 2. Am J Reprod Immunol. 2018. PMID: 30175479 Free PMC article. - Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States.
Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA. Losina E, et al. Clin Infect Dis. 2017 Oct 15;65(8):1266-1271. doi: 10.1093/cid/cix547. Clin Infect Dis. 2017. PMID: 28605504 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical